By continuing to use this site you consent to the use of cookies on your device. Find out more about our cookie policy and the types of cookies we use by clicking here
Woodford-Backed Prothena Plunges
Prothena has scrapped the development of its lead drug after mid-stage clinical tests failed, but key investor Neil Woodford is still backing the Irish biotech firm
Reckitt Benckiser Still Undervalued
Morningstar equity analysts are lowering their share price forecast for the consumer goods giant, but believe that the shares are still below their fair value
Morningstar Fund Ratings: Weekly Round-up
ANALYST RATINGS: This week fund analysts reveal a new rating for Fidelity, an upgrade for Stewart Investors and a downgrade for L&G
Commodity Futures
Gold
Light Crude
Natural Gas

Global Market Barometer

More